Published in J Health Econ on December 01, 1993
The 'NICE' approach to technology assessment: an economics perspective. Health Care Manag Sci (2004) 1.25
Inclusion of drugs in provincial drug benefit programs: Should "reasonable decisions" lead to uncontrolled growth in expenditures? CMAJ (2003) 1.18
Estimating the "avoidable" burden of disease by Disability Adjusted Life Years (DALYs). Health Care Manag Sci (2000) 1.07
Economic evaluations: a new avenue of outcome assessment in spinal disorders. Eur Spine J (2005) 0.93
Recommendations for increasing the use of HIV/AIDS resource allocation models. BMC Public Health (2009) 0.88
Bridging the gap between health and non-health investments: moving from cost-effectiveness analysis to a return on investment approach across sectors of economy. Int J Health Care Finance Econ (2008) 0.77
Geographic Resource Allocation Based on Cost Effectiveness: An Application to Malaria Policy. Appl Health Econ Health Policy (2017) 0.77
Decision rules for allocation of finances to health systems strengthening. J Health Econ (2016) 0.77
Internal validation of models with several interventions. Eur J Health Econ (2012) 0.76
A risk-adjusted approach to comparing the return on investment in health care programs. Int J Health Care Finance Econ (2004) 0.75
On the decision rules of cost-effectiveness analysis. J Health Econ (1993) 2.09
Shared decision-making in the medical encounter: what does it mean? (or it takes at least two to tango). Soc Sci Med (1997) 19.00
Decision-making in the physician-patient encounter: revisiting the shared treatment decision-making model. Soc Sci Med (1999) 10.94
The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. J Clin Oncol (1995) 6.08
What do we mean by partnership in making decisions about treatment? BMJ (1999) 5.31
A bedside decision instrument to elicit a patient's preference concerning adjuvant chemotherapy for breast cancer. Ann Intern Med (1992) 4.60
Controlling health expenditures--the Canadian reality. N Engl J Med (1989) 4.36
System for Health Area Resource Planning (SHARP): an application to Ontario medical school enrollment. CMAJ (1994) 4.11
Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be? J Health Econ (1992) 3.33
Quality-adjusted life years, utility theory, and healthy-years equivalents. Med Decis Making (1989) 3.26
Health care contingent valuation studies: a review and classification of the literature. Health Econ (1998) 3.13
The Early External Cephalic Version (ECV) 2 Trial: an international multicentre randomised controlled trial of timing of ECV for breech pregnancies. BJOG (2011) 2.97
Universal precautions to prevent HIV transmission to health care workers: an economic analysis. CMAJ (1990) 2.68
Cost-effectiveness ratios: in a league of their own. Health Policy (1994) 2.55
Needle exchange programs: an economic evaluation of a local experience. CMAJ (1997) 2.46
Analysis of fluorescence decay curves by means of the Laplace transformation. Biophys J (1975) 1.96
Patients' preferences for therapy in advanced epithelial ovarian cancer: development, testing, and application of a bedside decision instrument. Gynecol Oncol (1996) 1.91
Physician-patient-companion communication and decision-making: a systematic review of triadic medical consultations. Patient Educ Couns (2013) 1.89
Discounting in the economic evaluation of health care interventions. Med Care (1993) 1.89
Comparison of cervical, urethral, and urine specimens for the detection of Chlamydia trachomatis in women. J Infect Dis (1991) 1.87
The healthy-years equivalents: how to measure them using the standard gamble approach. Med Decis Making (1991) 1.73
Noninvasive positive pressure ventilation in the setting of severe, acute exacerbations of chronic obstructive pulmonary disease: more effective and less expensive. Crit Care Med (2000) 1.71
Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study. AIDS (1999) 1.70
Physician supply in Ontario: further observations on SHARP and the SHARP projections. CMAJ (1995) 1.67
Breast irradiation postlumpectomy: development and evaluation of a decision instrument. J Clin Oncol (1995) 1.66
Shared decision making in a publicly funded health care system. Policies exist to reduce the risk of conflict between individual and society. BMJ (1999) 1.65
Recognizing diversity in public preferences: the use of preference sub-groups in cost-effectiveness analysis. Health Econ (2001) 1.59
How to improve communication between doctors and patients. Learning more about the decision making context is important. BMJ (2000) 1.55
Newborn circumcision: an economic perspective. Can Med Assoc J (1984) 1.54
When do the "dollars" make sense? Toward a conceptual framework for contingent valuation studies in health care. Med Decis Making (1996) 1.53
Is it 'worthwhile' to continue treating patients with a prolonged stay (>14 days) in the ICU? An economic evaluation. Chest (1998) 1.47
Individual correlates of health service utilization and the cost of poor adjustment to chronic illness. Med Care (1990) 1.44
Mastectomy or lumpectomy? Helping women make informed choices. J Clin Oncol (1999) 1.42
Preoperative HIV testing: is it less expensive than universal precautions? J Clin Epidemiol (1993) 1.41
Effectiveness and efficiency of selective vs universal screening for chlamydial infection in sexually active young women. Arch Intern Med (1992) 1.41
Understanding economic evaluations: a review of the knee arthroplasty literature. Am J Knee Surg (1999) 1.38
The supportive care needs of newly diagnosed cancer patients attending a regional cancer center. Cancer (1997) 1.35
Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective. Arch Intern Med (1997) 1.34
Outcomes and costs of coronary artery bypass grafting: comparison between octogenarians and septuagenarians at a tertiary care centre. CMAJ (2001) 1.33
Chemotherapy waste reduction through shelf-life extension. Can J Hosp Pharm (1994) 1.29
Opportunity costs and uncertainty in the economic evaluation of health care interventions. Health Econ (2002) 1.25
Healthy-years equivalents versus quality-adjusted life years: in pursuit of progress. Med Decis Making (1994) 1.21
Characterising doctor-parent communication in counselling for impending preterm delivery. Arch Dis Child Fetal Neonatal Ed (2002) 1.21
When the bough breaks: provider-initiated comprehensive care is more effective and less expensive for sole-support parents on social assistance. Soc Sci Med (2001) 1.16
Reliability and intraoperative validity of preoperative assessment of standardized plain radiographs in predicting bone loss at revision hip surgery. J Bone Joint Surg Am (2001) 1.15
A cost-effectiveness analysis of the routine use of isoniazid prophylaxis in patients with a positive Mantoux skin test. Am Rev Respir Dis (1990) 1.13
Fluorescence decay studies of reduced nicotinamide adenine dinucleotide in solution and bound to liver alcohol dehydrogenase. Biochemistry (1976) 1.13
Effects of labelling on income, work and social function among hypertensive employees. J Chronic Dis (1984) 1.13
Economic evaluations of community-based care: lessons from twelve studies in Ontario. J Eval Clin Pract (1999) 1.12
Valuing outcomes in health care: a comparison of willingness to pay and quality-adjusted life-years. J Clin Epidemiol (1998) 1.12
Age-related changes in the redox status of rat muscle cells and their role in enzyme-aging. Mech Ageing Dev (1985) 1.09
The quality of QALYs (quality-adjusted-life-years): do QALYs measure what they at least intend to measure? Health Policy (1989) 1.08
Nanosecond decay studies of a fluorescence probe bound to apomyoglobin. Biophys J (1977) 1.06
Highly active antiretroviral therapy: pharmacoeconomic issues in the management of HIV infection. Pharmacoeconomics (2001) 1.05
Frequency and methodologic rigor of quality-of-life assessments in the critical care literature. Crit Care Med (1998) 1.05
Hospital selection for unit cost estimates in multicentre economic evaluations. Does the choice of hospitals make a difference? Pharmacoeconomics (1999) 1.05
Problem-solving counseling for caregivers of the cognitively impaired: effective for whom? Nurs Res (1999) 1.04
Evaluation of public investment in health care. Is the risk irrelevant? J Health Econ (1983) 1.04
Economic evaluations in the critical care literature: do they help us improve the efficiency of our unit? Crit Care Med (1996) 1.03
Aggregation of an amyloidogenic fragment of human islet amyloid polypeptide. Biochim Biophys Acta (2000) 1.02
The Control of Hypertension In Pregnancy Study pilot trial. BJOG (2007) 1.02
Long-lived tryptophan fluorescence in phosphoglycerate mutase. Biochemistry (1989) 1.01
Are health states "timeless"? The case of the standard gamble method. J Clin Epidemiol (1999) 1.01
Women's perceptions about treatment decision making for ovarian cancer. Gynecol Oncol (2003) 1.00
Developing a model of collaborative research: the complexities and challenges of implementation. Int J Nurs Stud (2000) 0.98
Time-resolved circularly polarized protein phosphorescence. Proc Natl Acad Sci U S A (1992) 0.98
Prospective care of elderly patients in family practice. Is screening effective? Can Fam Physician (1998) 0.98
A cross-cultural consumer-based decision aid for screening mammography. Prev Med (2000) 0.97
A review and economic evaluation of bronchodilator delivery methods in hospitalized patients. Arch Intern Med (1996) 0.96
A profile of users of specialty pain clinic services: predictors of use and cost estimates. J Clin Epidemiol (1992) 0.95
Willingness to pay for periodontal therapy: development and testing of an instrument. J Public Health Dent (1999) 0.94
Effect of routine use of a multiplex PCR for detection of vanA- and vanB- mediated enterococcal resistance on accuracy, costs and earlier reporting. Diagn Microbiol Infect Dis (2001) 0.94
Quenching of tryptophan phosphorescence in Escherichia coli alkaline phosphatase by long-range transfer mechanisms to external agents in the rapid-diffusion limit. Biochemistry (1991) 0.93
Assessing the value of a new pharmaceutical. A feasibility study of contingent valuation in managed care. Med Care (1998) 0.93
Evaluating health related quality of life: an indifference curve interpretation for the time trade-off technique. Soc Sci Med (1990) 0.93
Economic and policy implications of adopting paclitaxel as first-line therapy for advanced ovarian cancer: an Ontario perspective. J Clin Oncol (1997) 0.92
Nanosecond time-resolved circular polarization of fluorescence: study of NADH bound to horse liver alcohol dehydrogenase. Proc Natl Acad Sci U S A (1995) 0.91
Thermal switching between enhanced and arrested reactivation of bacterial glucose-6-phosphate dehydrogenase assisted by GroEL in the absence of ATP. J Biol Chem (1993) 0.90
Design and validation of a bedside decision instrument to elicit a patient's preference concerning allogenic bone marrow transplantation in chronic myeloid leukemia. Am J Hematol (1995) 0.90
Understanding newborn infant readmission: findings of the Ontario Mother and Infant Survey. Can J Public Health (2001) 0.89
Time-resolved room temperature protein phosphorescence: nonexponential decay from single emitting tryptophans. Biophys J (1994) 0.89
Time-resolved room temperature tryptophan phosphorescence in proteins. Methods Enzymol (1997) 0.89
Determination of the aggregation number of detergent micelles using steady-state fluorescence quenching. Biophys J (1993) 0.88
Comparison of the time-resolved absorption and phosphorescence from the tryptophan triplet state in proteins in solution. Photochem Photobiol (1998) 0.88
Modulation of stoichiometry of the sarcoplasmic reticulum calcium pump may enhance thermodynamic efficiency. Proc Natl Acad Sci U S A (1985) 0.88
Detection of a pH-dependent conformational change in azurin by time-resolved phosphorescence. Biophys J (1996) 0.87
Economic evaluations in the hip arthroplasty literature: lessons to be learned. J Arthroplasty (1999) 0.87
Characterization of sarcoplasmic reticulum adenosinetriphosphatase purified by selective column adsorption. Biochemistry (1984) 0.87
Potential savings from the adoption of nurse practitioner technology in the Canadian health care system. Socioecon Plann Sci (1983) 0.87
Phosphorescence reveals a continued slow annealing of the protein core following reactivation of Escherichia coli alkaline phosphatase. Biochemistry (1995) 0.87
The costs and effects of addressing the needs of vulnerable populations: results of 10 years of research. Can J Nurs Res (2001) 0.86
How can we meet the information needs of patients with early stage papillary thyroid cancer considering radioactive iodine remnant ablation? Clin Endocrinol (Oxf) (2011) 0.86
The diffusion of medical technology: a "prisoner's dilemma" trap? Socioecon Plann Sci (1986) 0.86
Systematic validation of disease models for pharmacoeconomic evaluations. Swiss HIV Cohort Study. J Eval Clin Pract (1999) 0.86
Economic evaluation of intravenous immune globulin therapy for Kawasaki syndrome. J Pediatr (1993) 0.86
Costs of postpartum care: examining associations from the Ontario mother and infant survey. Can J Nurs Res (2001) 0.86
Examining physician-patient-caregiver encounters: the case of Alzheimer's disease patients and family physicians in Israel. Aging Ment Health (2004) 0.86
Prediction of resource utilization and case cost for acute nonvariceal upper gastrointestinal hemorrhage at a Canadian community hospital. Am J Gastroenterol (1999) 0.85
Immediate surgery versus waiting list policy in revision total hip arthroplasty. An economic evaluation. J Arthroplasty (1997) 0.85
Circular dichroism and circular polarization of luminescence of reduced nicotinamide adenine dinucleotide in solution and bound to dehydrogenases. Biochemistry (1978) 0.84